// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























7277 Abstracts

NOYA I: A Prospective Randomized Trial of the Biodegradable Polymer NOYA Sirolimus-Eluting Stent Compared with the Durable Polymer FIREBIRD 2 Sirolimus-Eluting Stent in Patients with Coronary Artery Disease: 9-Month Angiographic and 24-Month Clinical Results

Bo Xu - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

sirolimus

SYNERGY Biodegradable Polymer Everolimus Eluting Coronary Stent: Porcine Vascular Compatibility and Polymer Safety Study

Gregory Wilson - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Long term Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in Real-World Practice: 5 year follow-up of the CREATE (multi-Center Registry of EXCEL Biodegradable Polymer Drug Eluting Stents) Study

Ya-Ling Han - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

sirolimus

Real Polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multi-center, randomized, prospective trial

Shao Liang Chen - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Rapacan

A Preliminary Study of Biodegradable Iron Stent in Mini-Swine Coronary Artery

Chao Wu - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Randomized comparison of Biolimus-eluting (Nobori) and Everolimus-eluting (Xience/Promus) stents in patients with multivessel coronary artery disease: 12-month follow-up data from COMPARE II study

Peter Smits - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Everolimus

Drug-eluting stent with biodegradable polymer in patients with STEMI short and long term outcomes: data from e-NOBORI and NOBORI 2 trials

Andres Iniguez - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Crofelemer

COMPARE II: One year Clinical Data for the treatment of small vessels (<2.75mm)

SH Hofma - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

COMPARE II 1 Year Outcomes of a large randomized all-comers study

Peter Smits - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Biolimus A9

First-in-human Evaluation of a Novel Sirolimus-eluting Stent with a Bioabsorbable Polymer for the Treatment of Single, De Novo, Non-complex Coronary Lesions

Erlon de Abreu-Silva - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

sirolimus

COMPARE II: 1 Year Clinical Data of the Treatment of Long Lesions (>20mm)

Peter Smits - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Multi Center, Prospective, Randomized, Single Blind, Consecutive Enrollment Evaluation a Novolimus-Eluting Coronary Stent System with Bioabsorbable Polymer Compared to a Zotarolimus-Eluting Coronary Stent System: 12- Month Clinical and 6-Month Angiographic and IVUS Results: the EXCELLA BD Study

Alexandre Abizaid - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

ZoMaxx

Nine Month Imaging and Twelve Month Clinical Results from the DESSOLVE II Randomized Trial of the MiStent SES with Absorbable Polymer

William Wijns - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Rapacan

Drug-Coated Balloon For De Novo Coronary Lesions: Results From The Valentines II Trial

Ron Waksman - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Efficacy and Safety of Drug-Eluting Balloon Compared to Drug-Eluting Stent for The Treatment of In-Stent Restenosis (ISR)

Myung-Hyun Kim - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

ZoMaxx

Real-world experience of the polymer-free rapamycin-eluting YUKON-Choice stent: five-year results from a prospective registry

Marc-Alexander Ohlow - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Rapacan

Proximal Coronary Artery Stenting: DES Versus BMS and LAD Versus the Rest

Fredrik Calais - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Clinical Outcome in Chinese Patients with Long Lesion or Small Vessel/Multivessel Disease Receiving XIENCE V Everolimus-Eluting Stent: Early Results From the SEEDS Study

Bo Xu - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Everolimus

Two-Year Outcomes after Implantation of XIENCE PRIME and XIENCE PRIME Long Lesion Stents in Patients with Coronary Artery Disease: Results of the SPIRIT PRIME Multicenter Pivotal Clinical Trial

Marco Costa - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Effect of stent inflation pressure and post-dilatation on the outcome of coronary artery intervention. a report of more than 90 000 stent implantations

Ole Frobert - Transcatheter Cardiovascular Therapeutics (TCT) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Copyright © 2026. QuantiNova All rights reserved